NewsRoom Articles - Page 1396 of 1463

FridayJan 13, 2017 1:29 pm

DelMar Pharmaceuticals (NASDAQ: DMPI) Given a ‘Buy’ Rating and $16 Price Target by Aegis Capital

Biotechnology company DelMar Pharmaceuticals (NASDAQ: DMPI) has been given a ‘Buy’ rating by Aegis Capital Corp. and a $16 price target (http://nnw.fm/wWJH9). The company was trading at $3.29 on January 11, 2016. To reach that price target, Aegis, in its initiation of coverage, said that it applied a 15x multiple after estimating the company’s 2022 EPS at $3.93, then discounting it by 30%. DelMar Pharmaceuticals has been developing its lead product candidate, VAL-083, as a chemotherapy for cancer. Specifically, VAL-083 would be used in the treatment of glioblastoma multiforme (GBM), the most common form of a fatal and aggressive brain…

FridayJan 13, 2017 12:44 pm

MassRoots, Inc. (MSRT) Achieves Incredible Growth in 2016

MassRoots, Inc. (OTCQB: MSRT), a company offering cannabis enthusiasts the chance to share their cannabis content while staying connected with news and the latest legislation regarding the drug through a specialized social media platform and iOS application, has shown significant growth in the rapidly developing cannabis industry. According to a SeeThruEquity update (http://nnw.fm/f5kvA), MassRoots achieved phenomenal growth in 2016, with revenue reaching $794,621 during the first three quarters of 2016, compared to just $63,982 during the same period of the previous year. This performance was attributed to the company’s ability to monetize its users, which increased by 1,140% as compared…

FridayJan 13, 2017 11:39 am

Moxian, Inc. (NASDAQ: MOXC) Raises $10 Million in 2016 Despite Drought in Technology Offerings

Moxian, Inc. (NASDAQ: MOXC) continues to buck the trend. Despite the dearth of technology issues in 2016, the company completed a successful best-efforts public offering of 2,501,250 shares of its common stock at a price of $4.00 per share in November 2016, raising $10 million in new capital. Now, Moxian is poised to extend its unique online-to-offline (O2O) platform to a wider market. Just as the NASDAQ uplisting raises the company’s investor visibility, this infusion of capital will be used to heighten awareness of Moxian and give it a larger footprint. With its new stash of cash, Moxian is set…

FridayJan 13, 2017 9:13 am

Net Element (NASDAQ: NETE) Targets Hospitality and Restaurant Industries with Technology

Net Element, Inc. (NASDAQ: NETE) is targeting two industries on the cusp of greater revolutionary technology investments: hospitality and restaurants. Net Element’s Unified Payments subsidiary recently entered into an agreement with ReservHotel (http://nnw.fm/bO01f), providing technology-driven payment acceptance services. To the restaurant industry, Net Element offers its Aptito cloud-based point-of-sale system (http://nnw.fm/3wmF1). The hotel industry had a terrific year in 2016, according to STR (http://nnw.fm/kp3Rd). For the week ended December 31, 2016, year-over-year, the industry had nearly flat occupancy, but the payoff was that its average daily rate (ADR) rose 2.2% to $132.79, and its revenue per available room (RevPAR) rose…

ThursdayJan 12, 2017 1:55 pm

ChineseInvestors.com, Inc. (CIIX) Offers Unique Path to Global Chinese Investor and Consumer Market

Founded in 1999, and with offices in the U.S. and China, ChineseInvestors.com, Inc. (OTCQB: CIIX) acts as a growing Chinese-language investment information and services conduit to the global Chinese investor community. Primarily through its websites, the company provides different levels of investment information, both free and via subscription, including information on the U.S. market and foreign currencies, covering sectors as well as companies, real-time market news and analysis, quotes, charts, and research tools. The company is led by chairman and CEO Warren Wang, COO Brett Roper, CFO Paul Dickman, and Director James Toreson. The company’s stated mission is to ‘educate…

ThursdayJan 12, 2017 1:16 pm

CytoDyn (CYDY) Seeks Breakthrough Therapy Designation for Innovative HIV Therapy PRO 140

A growing number of human immunodeficiency virus (HIV) patients are in need of new treatment as they start facing issues of drug resistance and their regular therapies are becoming less effective. Unfortunately, new treatment options are scarce to virtually non-existent, as the standard of care for HIV patients remains a combination of different classes of antiretroviral medications at different stages of the infection. Driven by the strong belief that HIV patients, including those newly diagnosed, should receive the treatment they need as soon as possible, Vancouver, Washington-based biotech company CytoDyn Inc. (OTCQB: CYDY) has developed a new therapy, a viral-entry…

ThursdayJan 12, 2017 11:03 am

Net Element, Inc. (NASDAQ: NETE) Subsidiary PayOnline Adds Russia’s Leading Short-Term Accommodation Rental Service as Client

Before the opening bell, Net Element, Inc. (NASDAQ: NETE) announced that its PayOnline subsidiary has entered into a new partnership with Sutochno.ru, Russia’s premier C2C short-term booking service, through which PayOnline will be providing online payment acceptance services for the platform. Similar to Airbnb, Sutochno.ru gives users the tools to book short-term accommodation in markets across Russia. The site currently features more than 70,000 property listings, and it attracted over 700,000 guests in 2016. Sutochno.ru differentiates itself from Airbnb by offering a more attractive pricing model that eliminates commission charges for guests and minimizes fees for hosts. Moving forward, PayOnline’s…

ThursdayJan 12, 2017 9:29 am

GainClients, Inc. (GCLT) has Disruptive Marketing Solutions for Real Estate Professionals

GainClients, Inc. (OTC: GCLT) is disrupting the real estate marketing and advertising industry. Its GCard mobile technology platform ‘allows the loan originator, the real estate sales person, or the “title guy” to succeed in this marketplace’. In an interview with RedChip (http://nnw.fm/23hTv), CEO of GainClients, Ray Desmond, discussed the concepts behind his company’s business model. GainClients, it appears, is attempting to monetize the store of data and knowledge amassed by CEO Ray Desmond over his 36 years in the real estate industry. “We’ve created our daily opportunities product that allows us to catch that person that’s selling their house that…

WednesdayJan 11, 2017 4:28 pm

Cytosorbents Corp. (NASDAQ: CTSO) Expected to Announce Doubling in Sales for 2016

Cytosorbents Corp. (NASDAQ: CTSO), a critical care-focused immunotherapy company engaged in the research, development, and commercialization of medical devices, most prominently its platform blood purification technology that incorporates a proprietary adsorbent polymer technology, recently pre-announced unaudited results (http://nnw.fm/P4Yaz) for fiscal 2016 ahead of its Form 10-K filing. Cytosorbents expects to announce between $8.1 and $8.3 million in Cytosorb sales for the whole of 2016. This equates to more than double the total from the previous year. Cytosorb is the company’s flagship product, a blood filter that helps treat deadly inflammation in critically-ill and cardiac surgery patients across the globe. In…

WednesdayJan 11, 2017 2:49 pm

Aegis Restates ‘Buy’ Rating on Shares of Rosetta Genomics Ltd. (NASDAQ: ROSG)

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a company in the business of developing and commercializing MicroRNA-based and other molecular diagnostics, recently had its ‘Buy’ rating restated by Aegis Capital Corp. (http://nnw.fm/LV2Yy) with a price target of $3.50 per share. This was based on Aegis’ 2017 revenue estimate of $17.7 million with a multiple of 4X. The company update was released after Rosetta Genomics Ltd. announced a new collaboration to determine biomarkers that can predict response to Opdivo, a PD-1 immunotherapy. In addition to the above, Aegis Capital Corp. announced expectations for Rosetta Genomics’ cash deliverables to be over $9 million by…

Financial news and publishing for public and private companies

Contact us: 512.354.7000